OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.75
−0.04%Oct 19, 2026, 11:30 UTC
Organon & Co. said it plans to release its third-quarter 2026 financial results through its regularly scheduled Form 10-Q filing and disclose non-GAAP measures with reconciliations to comparable GAAP measures.
Source:Oct 1, 2026, 12:00 UTC
Organon announced it will present new real-world analyses of VTAMA (tapinarof) cream, 1% for eczema patients at the 2026 Fall Clinical Dermatology Conference.
Source:Sep 29, 2026, 10:30 UTC
Sun Pharmaceutical Industries plans to raise about $1 billion through a domestic bond sale in India to repay a bridge loan taken for its acquisition of Organon.
Sep 29, 2026, 01:38 UTC
Sun Pharma entered an in-licensing agreement for a PCSK9 inhibitor, making upfront, milestone, and royalty payments, with the product receiving European Commission approval on 21 September 2026.
Source:Sep 18, 2026, 09:45 UTC
Organon signed agreements with Population Services International India and Ipas Development Foundation as recipients of its 2026 Her Health Grants, supporting adolescent girls' health in Bihar and contraceptive access in Uttar Pradesh.
Source:Sep 16, 2026, 09:09 UTC
Alibaba Health Pharmacy announced a three-year strategy to shift from online medicine purchasing to bringing medicines closer to users and launched the 'Drug Full-Stack' strategic partnership with Sansheng Mandi, Daan Pharmaceutical, Daiichi Sankyo (China) Investment, and Organon.
Source:Sep 14, 2026, 11:30 UTC
The US FDA accepted for review Organon's supplemental New Drug Application for MIUDELLA, a hormone-free intrauterine device, seeking to extend its approved US use from 3 to 6 years.
Source:Aug 1, 2026, 13:54 UTC
Sun Pharmaceutical Industries' proposed acquisition of Organon has been approved by shareholders.
Source:Jul 23, 2026, 15:07 UTC
Shareholders of Organon & Co. approved the merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting.
Source:Jul 4, 2026, 15:45 UTC
Sun Pharma announced it is buying American pharmaceutical company Organon in a deal valued at about $11.75 billion, including debt.
Source:Jul 1, 2026, 18:00 UTC
Organon & Co. reported quarterly earnings on April 30th, with EPS of $0.71 missing consensus of $0.83 and revenue of $1.46 billion missing consensus of $1.49 billion.
Source:Jul 1, 2026, 18:00 UTC
Organon & Co. shares hit a new 52-week high of $13.60 on Wednesday.
Jun 23, 2026, 09:30 UTC
Organon Canada and Shanghai Henlius Biotech launched BILDYOS and TUZEMTY, biosimilars to PROLIA and XGEVA, in Canada.
Source:Jun 22, 2026, 11:30 UTC
Organon completed a global licensing agreement with Sebela Pharmaceuticals to exclusively license MIUDELLA, a hormone-free copper IUD.
Source:Jun 18, 2026, 10:00 UTC
Organon and Samsung Bioepis expanded their agreement to commercialize PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA® (ustekinumab), in Canada.
Source:Jun 12, 2026, 14:16 UTC
Organon received FDA approval to expand the use of TOFIDENCE for severe cytokine release syndrome and certain hospitalized COVID-19 patients.
Source:Jun 2, 2026, 16:04 UTC
Brodsky & Smith is investigating potential breaches of fiduciary duty by Organon & Co.'s board in connection with the sale of Organon to Sun Pharmaceutical Industries Limited.
Source: